Heron Therapeutics
HRTX
167 hedge funds and large institutions have $126M invested in Heron Therapeutics in 2026 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 52 increasing their positions, 43 reducing their positions, and 29 closing their positions.
21% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 43
7% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 29
2% less funds holding
Funds holding: 170 → 167 (-3)
2.14% less ownership
Funds ownership: 85.34% → 83.2% (-2.1%)
39% less capital invested
Capital invested by funds: $207M → $126M (-$81.2M)
47% less call options, than puts
Call options by funds: $904K | Put options by funds: $1.71M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$11.4M |
| 2 |
PFCS
Pale Fire Capital SE
Prague,
Czech Republic
|
+$1.44M |
| 3 |
TC
Tejara Capital
London,
United Kingdom
|
+$1.4M |
| 4 |
CPC
Congress Park Capital
Saratoga Springs,
New York
|
+$1.12M |
| 5 |
RB
Richmond Brothers
Jackson,
Michigan
|
+$1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$14.5M |
| 2 |
Jane Street
New York
|
-$1.59M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.55M |
| 4 |
Two Sigma Investments
New York
|
-$790K |
| 5 |
Morgan Stanley
New York
|
-$522K |
HRTX Hedge Fund Activity: Q1 2026 in Review
167 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q1 2026, worth a combined $126M — down 39% from $207M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new HRTX positions and 29 closed out — a net gain of 2 holders — while 52 added to existing stakes and 43 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $11.4M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $14.5M sold.
- 167 institutional investors held Heron Therapeutics (HRTX) as of Q1 2026, down from 170 in Q4 2025.
- Funds reported $126M of Heron Therapeutics stock for Q1 2026, down 39% quarter-over-quarter.
- 31 funds opened new Heron Therapeutics positions in Q1 2026 and 29 closed out, a net change of +2 holders.
- The largest Heron Therapeutics buyer in Q1 2026 was OrbiMed, an estimated $11.4M added.
- The largest Heron Therapeutics seller in Q1 2026 was Adage Capital Partners, an estimated $14.5M sold.
Based on aggregated 13F filings for Q1 2026.